Thoracic surgeon Daniela Molena leads clinical trials to improve outcomes for people with esophageal cancers.
At any time Memorial Sloan Kettering Cancer Center is conducting hundreds of clinical trials to improve care for many types of cancer. Use the tool below to browse our clinical trials that are currently enrolling new patients. Each listing explains the purpose of the trial, the trial’s eligibility criteria, and how to get more information.
The list below includes clinical trials for adult cancers. Please visit our pediatric cancer care section to find a pediatric clinical trial.
The overall goal of this study is to see if adding inotuzumab ozogamicin to standard chemotherapy maintains or improves treatment effectiveness in young patients with high-risk B cell acute lymphoblastic leukemia (B-ALL). Inotuzumab ozogamicin contains an antibody (inotuzumab) linked to a type of chemotherapy (calicheamicin). Inotuzumab attaches to cancer cells in a targeted way and delivers calicheamicin to kill them.
For people with newly diagnosed acute myeloid leukemia (AML), the more leukemia cells are destroyed, the better their long-term outcomes. In this study, researchers want to see adding venetoclax to standard chemotherapy (daunorubicin/cytarabine) or giving it with azacitidine works better than standard therapy for getting rid of the small amount of remaining leukemia cells. The people in this study include young adults with intermediate-risk AML.
The purpose of this study is to assess the safety and effectiveness of treatment with axitinib and nivolumab immunotherapy for people with advanced mucosal melanoma that has not yet been treated. Axitinib blocks the development of blood vessels that cancer cells need to grow and spread ("angiogenesis"). Nivolumab boosts the ability of the immune system to detect and destroy cancer cells.
Researchers are doing this study to see how well COM701 immunotherapy works when used as maintenance therapy for ovarian cancer. Maintenance therapy helps keep cancer from growing again after it shrank or stopped growing following earlier treatment.
Prostate cancers initially need the male hormone testosterone for growth. Hormone therapies that lower the level of testosterone are among the most effective treatments for prostate cancers that have spread to other organs (metastasized). The benefits of hormone treatments do not last, however. Over time, many prostate cancers continue to grow despite hormonal therapies; these are called "castration-resistant prostate cancers" (CRPC).
Researchers are comparing mosunetuzumab to the usual treatment (rituximab) for nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL). They want to see if one drug is more effective than the other to shrink the cancer with a long-lasting response.
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
This study is assessing a blood test that may tell doctors which people need immunotherapy after bladder cancer surgery. Many types of tumors lose cells into the bloodstream and shed their DNA. This circulating tumor DNA (ctDNA) may be found before changes in a tumor can be seen on scans.
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
Researchers are finding the best dose of ASP2138 to use in people with advanced digestive cancers. The people in this study have cancer of the pancreas, stomach (gastric cancer), or junction between the esophagus and stomach (gastroesophageal junction cancer). In addition, their cancers make a protein called CLDN 18.2 and keep growing even after treatment.
